Why Goldman Sachs Trimmed Insulet Corporation (PODD) Price Target Despite Strong Q1 Results

We recently compiled a list of the 8 Most Oversold Large Cap Stocks to Buy. Insulet Corporation (NASDAQ:PODD) is one of the most oversold stocks.

TheFly reported on May 7 that PODD saw its valuation outlook revised as Goldman Sachs reduced its price target to $237 from $277 while maintaining a Buy rating on the shares. The firm noted that the company’s first-quarter results and updated guidance initially appeared strong, but concerns emerged regarding the growth trajectory after second-quarter U.S. revenue guidance came in below full-year expectations, and annual targets were only reiterated despite a first-quarter beat. Management also attributed the slower-than-expected start to the year to stronger seasonality effects linked to insurance deductible resets, which impacted early demand trends.

Why Goldman Sachs Trimmed Insulet Corporation (PODD) Price Target Despite Strong Q1 Results

Moreover, earlier, on May 4, Insulet Corporation (NASDAQ:PODD) reported the enrollment of the first participant in its EVOLVE study evaluating a fully closed-loop automated insulin delivery system for individuals with type 2 diabetes. The study represents an important step in advancing next-generation diabetes management technology. The system is designed to automatically adjust insulin dosing through an advanced algorithm trained on both real-world and simulated patient data, aiming to improve safety and glucose control while reducing the burden on patients and healthcare providers. The development reflects PODD’s continued focus on innovation in diabetes care solutions.

Insulet Corporation (NASDAQ:PODD) is a medical device company based in Acton. It develops the Omnipod tubeless insulin delivery system, including Omnipod 5, which helps people with diabetes manage insulin more easily and effectively.

While we acknowledge the risk and potential of PODD as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than PODD and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Cancer Stocks to Buy for the Long Term and 10 Most Popular Stocks on Robinhood in 2026.

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 1759070 - 1